Cassava Sciences Newsroom

Buy Aehr Test Systems, Sell Cassava Sciences

Baystreet.caJul 24 10:14 ET

Here's How Much $1000 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today

BenzingaJul 23 12:30 ET

Cassava Shares Rise After Incoming Chairman Gives Timeline for Alzheimer's Drug Study Read Out

MT NewswiresJul 22 14:39 ET

Cassava Sciences Advances Alzheimer's Drug Through High-Stakes Phase 3 Trials

BenzingaJul 22 14:03 ET

Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session

BenzingaJul 22 13:28 ET

IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday

BenzingaJul 22 11:28 ET

Why Cassava Sciences Stock Is Skyrocketing Today

Yahoo FinanceJul 22 11:27 ET

Express News | Cassava Sciences Shares Are Trading Higher After the Company Announced Its First Phase 3 Trial Is Expected to Conclude by December and Its Second Phase 3 Trial Is Expected to Conclude by June 2025

BenzingaJul 22 10:25 ET

Cassava Sciences Chairman Shares Insights in Open Letter

TipRanksJul 22 08:27 ET

Express News | Cassava Sciences Shares up 3.2% Premarket; Data From Late-Stage Trial of Co's Alzheimer's Drug Is Expected in December

ReutersJul 22 08:23 ET

Express News | Cassava Sciences Executive Chairman Rick Barry Issues An Open Letter To "Shareholders, Employees, Principal Investigators, Patients And Their Loved Ones" On July 21, 2024

BenzingaJul 22 08:18 ET

Express News | Cassava Sciences' Phase 3 Trial Expected To Conclude By December 2024 With 804 Patients; Second Trial With 1,125 Patients To End By June 2025; Successful Results Could Be Revolutionary

BenzingaJul 22 08:17 ET

Express News | Cassava Sciences : Board Is 100% Committed to Completing Phase 3 Program, Releasing Results on Time

ReutersJul 22 08:15 ET

Express News | Cassava Sciences : Will Inform Cassava Community of Material News About Co and Clinical Trials

ReutersJul 22 08:15 ET

Express News | Cassava Sciences Inc: Second Phase 3 Trial Is Expected to Conclude by June 2025

ReutersJul 22 08:14 ET

Express News | Cassava Sciences Inc: First Phase 3 Trial Is Expected to Read Out by December 2024 - SEC Filing

ReutersJul 22 08:14 ET

Cassava Sciences Analyst Ratings

BenzingaJul 19 06:41 ET

H.C. Wainwright Maintains Cassava Sciences(SAVA.US) With Hold Rating

Moomoo NewsJul 19 06:31 ET · Ratings

H.C. Wainwright Sticks to Their Hold Rating for Cassava Sciences (SAVA)

TipRanksJul 19 06:17 ET

Sector Update: Health Care Stocks Advance Late Afternoon

MT NewswiresJul 17 15:58 ET